本文由小咖机器人翻译整理

期刊来源：Ann Intern Med

原文链接：https://doi.org/10.7326/M24-0613

摘要内容如下：

2023年，肺病学领域取得了重大进展。本文重点介绍了与哮喘、慢性阻塞性肺病（COPD）、间质性肺病、胸膜疾病和睡眠呼吸障碍相关的实践进展和变化。一篇文章回顾了研究呼吸道合胞病毒疫苗接种效果的数据，呼吸道合胞病毒是一种在全球范围内造成破坏性影响的呼吸道病毒性疾病。四项研究评估了各种治疗方法在COPD中的作用，包括dupilumab、ensifentrine、肺康复计划和肺减容与支气管内瓣膜。另一项研究探讨了正压通气对睡眠呼吸障碍和近期卒中患者血管事件的影响。利妥昔单抗和霉酚酸酯联合治疗非特异性间质性肺炎患者的无进展生存期是另一项研究的主题。我们还强调了评估胸膜疾病患者的最新临床建议，以及分析吸入糖皮质激素作为COPD双重治疗补充的有效性的系统综述。

英文原文如下：

Abstracts

The field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifentrine, pulmonary rehabilitation programs, and lung volume reduction versus endobronchial valves. Another study explores the effect on vascular events of positive-pressure ventilation in patients with sleep-disordered breathing and recent stroke. The use of combination therapy with rituximab and mycophenolate mofetil on progression-free survival in patients with nonspecific interstitial pneumonia is the topic of another study. We also highlight an update of clinical recommendations for the evaluation of patients with pleural disorders and a systematic review analyzing the effectiveness of inhaled corticosteroids as a supplement to dual therapy for COPD.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。